Tumour necrosis factor inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients
نویسندگان
چکیده
منابع مشابه
Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.
OBJECTIVE To study the effectiveness of tumour necrosis factor alpha (TNFalpha) inhibitor treatment for sarcoidosis refractory to conventional treatments. METHODS Five patients (two men, three women) were treated with infliximab. All patients received a loading dose of 3 mg/kg at 0, 2, and 6 weeks and then maintenance infusions every 4-8 weeks. Patients had their dose increased or the dosing ...
متن کاملTumor necrosis factor-alpha inhibitor treatment for sarcoidosis
Sarcoidosis is a chronic multisystem disease of unknown etiology, characterized by noncaseating granulomatous infiltration of virtually any organ system. Treatment is often undertaken in an attempt to resolve symptoms or prevent progression to organ failure. Previous studies have suggested a prominent role for tumor necrosis factor-alpha (TNF-alpha) in the inflammatory process seen in sarcoidos...
متن کاملRheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
UNLABELLED Rheumatoid arthritis is one of the commonest autoimmune diseases. It is a chronic, progressive, systemic inflammatory disorder affecting the synovial joints and typically producing symmetrical arthritis. If left untreated, it leads to joint destruction and thus deformity and disability.In the recent years, advances in molecular biology have led to a variety of new treatment approache...
متن کاملAntagonism of tumour necrosis factor a in refractory asthma
Asthma that is refractory to treatment with inhaled corticosteroids affects 5–10% of patients with asthma; it is an important health and economic problem in the UK and most industrialised nations. It is estimated that J17.7 billion is spent on asthma healthcare per annum in Europe, of which a disproportionately large amount is attributed to patients with refractory asthma, on average six times ...
متن کاملTofacitinib for the treatment of tumor necrosis factor-α inhibitor refractory esophageal Crohn’s disease: a case report
BACKGROUND Esophageal Crohn's disease is reported as a rare manifestation, although its prevalence may be underestimated because upper endoscopies are not routinely performed in asymptomatic adults. Tofacitinib, an oral janus kinase inhibitor, is a new biologic that has shown promise in the treatment of ulcerative colitis and may be effective in the treatment of Crohn's disease according to pha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of the Rheumatic Diseases
سال: 2004
ISSN: 0003-4967
DOI: 10.1136/ard.2002.004226